Historical Perspective of Medical Products of Human Origin (MPHO)

Dr. Luc Noël, Advisor, MPHO

​

 

PLENARY SESSION 2: Traceability Challenges

Chairs: Prof. Dr. Jeremy Chapman and Dr. Ruth Warwick

​

​

The Overarching Traceability Needs for MPHO

Dr. Axel Rahmel, German Organ Transplant Foundation (DSO)

​

 

The Challenge of Ensuring MPHO Traceability Across Multiple Professional Spheres of Activity

Dr Aurora Vassanelli, Italian National Transplant Centre (CNT)

​

 

FDA's Regulatory Framework for Ensuring Traceability of Blood and Blood Components

Dr. Wendy Paul, US Food and Drug Administration (FDA)

​

​

PLENARY SESSION 3: Implications of Unregulated Activities for Patient Safety

Chairs: Dr. Ineke Slaper-Cortenbach and Dr. Ziggy Szczepiorkowski

​

​

Overview of MPHO Patient Safety in Regulated as well as in Unregulated Environments

Prof. Dr. Jeremy Chapman, Medicine and Cancer at Westmead Hospital, Australia

​

​

Unproven Therapies and Patient Safety

Dr. Mickey Koh, WBMT Graft Processing and Cellular Therapy Committee/ISCT task force

​

 

Patient Safety, Ethics, and Approvals in CAR T Cell Therapy

Dr. Bruce Levine, President-Elect International Society for Cell and Gene Therapy (ISCT)

​

​

PLENARY SESSION 5: Celebration of the 25th Anniversary of ICCBBA: Ensuring Transparency on a Global Basis

Chairs: Mrs. Diane Wilson and Mr. Paul Ashford

​

 

One World Award Speech: Continental Unite – Past and Future Traceability of Substances of Human Origin

Ms. Suzanne Butch and Dr. Jørgen Georgsen

​

 

PLENARY SESSION 6: Scientific and Ethical Practice: Future Challenges

Chairs: Prof. Dr. Martin Hildebrandt and Dr. Kelly Tilleman

 

 

What are the Current Challenges of the Ethical Use of MPHO?

Dr. José Nunez, World Health Organization - Geneva

 

 

Genetic Manipulation in Human Reproduction: What are the Challenges?

Dr. Ewa Bartnik, WHO expert advisory group on developing global standards for governance and oversight of Human genome editing

 

 

PLENARY SESSION 7: Vigilance and Surveillance of MPHO – the Notify Project and Other International Initiatives

Chairs: Prof. Timothy Pruett and Dr. Salwa Hindawi

 

 

EU Strategies for the Vigilance and Surveillance of Substances of Human Origin

Dr. Deirdre Fehily, Directorate-General for Health and Food Safety, European Commission (DG SANTE)

​

​

Monitoring the Occurrence of Adverse Events Associated with the Use of Medical Products of Human Origin in the U.S.

Dr. Jefferson Jones, US Centers for Disease Control and Prevention (CDC)

​

 

How the NOTIFY Project can Improve the Safety of Transfusion/Transplantation/Application of MPHO.

Dr. Aurora Navarro Cantullera, The Catalan Transplant Organization (OCATT)

​

​

PLENARY SESSION 9: Healthcare Informatics and the Role of New Technologies

Chairs: Prof. Dr. Martin Hildebrandt and Dr. Jørgen Georgsen

​

Cloud, Block Chain and Related Technologies: MPHO Impacts and Opportunities

Mr. Wayne Bolton, Australian Red Cross Blood Service and chair of ICCBBA, TAG-Information Technology Committee

 

Ethical Aspects of Artificial Intelligence in Medicine

Dr. Stuart McLennan, Technical University Munich, Germany